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Translational science consists of research and development that integrates multiple resources to expedite the
successful treatment of disease. The International Park of Translational BioMedicine (IPTBM) is currently being
developed within the interface between Zhejiang Province and Shanghai Municipality. IPTBM has been designed to
pioneer comprehensive biomedical research that spans the continuum from the education of young scientists to
providing the infrastructure necessary for clinical testing and direct observation to better understand human
biology while promoting viable commercial results within a vibrant biotechnology community. IPTBM’s goal is to
attract global partners organized around five fundamental pillars: 1) Institutional Development,
2) Project Implementation, 3) Development and Production, 4) Investment and 5) Regulatory Clusters to address the
needs of an international platform of scientists, institutes, universities, commercial enterprises, investors, politicians,
and other stakeholders. The IPTBM differs from existing models including CTSA’s (US, NIH) technology because of its
comprehensive approach to merge education, research, innovation, and development to translate clinical and
public health needs into target-oriented and cost-efficient projects.
Keywords: Translational medicine, International, Projects, Development, Management, StrategyA big challenge exists in trying to translate scientific ideas
into actual experiments, the results of basic research into
clinical application, products into commercial value, and
research results into policies and regulations. It is also
challenging to expand the development of translational
science to learn the limitations and potentials of current
treatment approaches from direct human observation.
Translational research has been defined Bench to Bedside
but where the need for the process to extend also from
Bedside to Bench, creating a two-way path, was empha-
sized a decade ago by Marincola [1]. As a result, the
process of translational science needs to include not only
the insular participation of scientists, clinicians, and
universities, but also commercial organizations, ethicists,
regulatory agencies, and other entities to collaborate to-
wards guarantee the most effective, useful and safe* Correspondence: xiangdong.wang@clintransmed.org
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reproduction in any medium, provided the orapproach to produce benefit to mankind. The Inter-
national Park of Translational BioMedicine (IPTBM) was
planned and it is scheduled to be launched in January of
2013 in Southern China within the interface between the
Zhejiang Province and Shanghai Municipality; IPTBM is
one of several research and development parks within the
new area of innovation and development known as Sino
Science & Technology Park of Zhangjiang-Hangzhou Bay.
It consists of 65 square kilometers and it is sponsored by
both local and central government resources. The Park
aims to gather global scientific resources that will include
individual scientists, academic institutions, entrepreneurs,
investors, and regulatory experts in translational biomedi-
cine, in order to create an international platform that
spans the continuum comprising education, innovation,
development, marketing, regulation and, investment. The
Park will accomplish this goal by establishing a new, envir-
onmentally sound, high-technology, collaboration-based
community.
The IPTBM has been designed to learn from the col-
lected experiences of two major efforts, the creation of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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by the National Institutes of Health in the United States,
and in the global development of technology parks. As
part of the NIH Roadmap for Medical Research [2],
institutions were encouraged to reengineer resources
and programs of clinical and translational research. The
Clinical and Translational Science Awards (CTSA) pro-
gram was created and is currently sponsored by the
National Center for Advancing Translational Sciences at
the NIH. The CTSA program attempted to reengineer
the flow of resources to strengthen the full spectrum of
translational research and improve the quality and effi-
ciency of the process. IPTBM will also identify and reen-
gineer current resources associated with translational
research to increase and optimize the value of transla-
tional experts and centers [3]. Beyond the scope of the
CTSA program, however, the IPTBM plans to attract and
gather global powers and resources organized around five
fundamental pillars defined as 1) Institutional Develop-
ment, 2) Project Implementation, 3) Development and
Production, 4) Investment and 5) Regulatory Clusters.
Institutional Development Clusters will group institu-
tions of translational biomedicine owned, sponsored, or in
partnership with internationally recognized universities,
schools, or enterprises. The Project Clusters will foster in-
dividual investigator-generated projects with the potential
for directed application and commercialization. Develop-
ment & Production Clusters, the downstream facet of
translational research, will include companies supported
by the common aggregation of infrastructure, facilities,
and production capacities. Clusters for investments and
for regulatory groups will provide financial support from
private and public sectors, administrative assistance from
local and national management, and facilitate commercial
development and marketing.
IPTBM also aspires to develop an advanced plat-
form for graduate education and become a professional
incubator generating future-leading scientists in transla-
tional biomedicine. Zerhouni emphasized the import-
ance and difficulties of recruiting, mentoring, and
retaining an international assembly of qualified clinical
and translational scientists who can conduct truly
innovative patient-oriented research and development,
work under the pressures of delivery demands, and
perform outstanding research efficiently leading to an
optimal end result [4]. Unlike other existing technology
parks, IPTBM will provide educational programs in
clinical and translational research offering graduate
degrees under the supervision of internationally recog-
nized faculty and mentors. The Institutional Clusters
are expected to identify recognized and qualified global
level mentors to assure the quality of the educational re-
search program [5]. The Institutes in IPTBM will
assume full responsibility for the training of clinical andtranslational scientists and the assessment and develop-
ment of relevant disciplines and sub-disciplines.
IPTBM intends to provide the port where transla-
tional research projects can softly land and be trans-
ferred through the critical phases of development and
regulatory application, especially in China. IPTBM can
foster and accelerate projects exhibiting the potential
for commercial application, generated by the Institute
of Translational Biomedicine and individual scientists,
early phase enterprises, or licensing sectors, through
their maturation or late phase development and even
into production or commercialization. Different from
CTSAs and business incubators like science parks, the
IPTBM with its Institutional Clusters will provide the
full spectrum of requirements for effective biomedical
translation. IPTBM will assist scientists, institutes, and
companies in the development of the reputation and
market recognition of the projects and/or products,
evaluation and recruitment of development budgets and
investments, or minimization and avoidance of possible
risks and damages during development and marketing.
Criteria to measure the success of IPTBM will include
business objectives, rates of successful conversion from
research projects to commercial application, expansion
of a high quality scientific community, and the develop-
ment of education and innovation projects.
The IPTBM will play a comprehensive role in driving
biomedical investigation. CTSAs generally support infra-
structure and resources for clinical research, provide a
national consortium of medical research institutions that
can work together to improve clinical and translational re-
search and enhance the efficiency and quality. Innovation
science and technology parks or incubators mainly pro-
vide infrastructure and administrative assistance to foster
developing scientific ideas into projects with commercial
potential and help the initial formation of commercial
companies. The IPTBM will establish a centralized entity
in which the clusters that combine the components rele-
vant to translational research can converge to integrate
education, innovative research and development, project-
oriented activities, and application-dominated strategies
that will also require business development, external in-
vestment, and regulation. It is different from the concept
of clinical and translational medicine as integrative and
practical science which integrates clinical research with
modern methodologies in systems and computational
biology, and high-throughput analyses [6,7]. For example,
clinical and translational medicine can foster the imple-
mentation of human tissue banking, and the development
of bio-banks linked to high quality clinical data bases, for
identification of clear phenotypes relevant to stratification
of patients receiving standard or experimental therapies.
However, the Park will act as the key player to trigger
innovation and project development, to help and develop
Wu et al. Journal of Translational Medicine 2013, 11:8 Page 3 of 3
http://www.translational-medicine.com/content/11/1/8subsidiaries from existing organizations as peninsulas ra-
ther than as islands and as extensions of the company’s
strategic domain rather than as isolated outposts [8]. The
Park will encourage both formal and informal channels of
communication between corporate activities of parent
companies and their subsidiaries and to give subsidiaries
more authority to carry their ideas through to completion.
The Park will seed economic support to scientists, insti-
tutes, early stage projects, and corporate subsidiaries, be
attractive to investors and financial supporters not only
for research and development of projects, but also for edu-
cation and investigation of clinical needs, development of
translational principles, and establishment of public health
policies and regulations. However, there are many more
challenges that the IPTBM has to face and solve, such as a
fragmented infrastructure, lack of adequately trained
investigators, bureaucratic and regulatory burdens, or lack
of support by the public [9].
In conclusion, research and development in translational
science will integrate scientists, clinicians, universities,
companies, ethical and advisory committees, governmental
regulatory agencies, and, indirectly, governments. The
International Park of Translational BioMedicine is designed
to lead this integrative approach to create a vibrant inter-
national community of experts among the varied critical
field relevant to effective biomedical translation.
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